COMMUNIQUÉS West-GlobeNewswire

Invention of DNA "Page Numbers" Opens Up Vast Possibilities for the Bioeconomy
26/01/2026
A major technological advance in DNA writing enables researchers to construct and create in the language of biology PASADENA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- The power of artificial intelligence (AI) and [...]
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
26/01/2026
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of [...]
New Clinical Data Demonstrate that VIVUS’ QSYMIA® in Combination with Digitally Enhanced Lifestyle Interventions (DELI) Leads to Significantly Greater Reductions in Weight and Cardiovascular Risk Compared with DELI Alone in Adults with Obesity
26/01/2026
— Participants in the combined treatment group lost significantly more weight at 3, 6, and 12 months and were more likely to lose 5%, 10%, or >15% of their body weight at 12 months compared with DELI alone CAMPBELL, [...]
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
26/01/2026
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Indivior Announces Completion of Redomiciliation to the United States
26/01/2026
RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior [...]
Cannara publie ses résultats pour le premier trimestre de l’exercice 2026, enregistre de nouveaux résultats financiers records, accroît ses parts de marché et poursuit sa stratégie d’expansion disciplinée
26/01/2026
Nouveaux résultats financiers records : revenus totaux de 30,1 millions de dollars, marge brute avant ajustements de la juste valeur de 13,5 millions de dollars, soit 45 %, et BAIIA ajusté de 8,8 millions de dollars 1 [...]
Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
26/01/2026
New Record Financial Results: Total revenues of $30.1 million, gross profit before fair value adjustments of $13.5 million or 45% and Adjusted EBITDA of $8.8 million 1 , supported by operating cash flows of $8.0 million [...]
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
26/01/2026
Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB [...]
Sharps Technology Reports Strong Solana Staking Income
26/01/2026
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”), a medical device company implementing a Solana-based digital asset treasury strategy, today issued an update on its treasury [...]
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
26/01/2026
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in [...]
Nxera Pharma Webinar Presentation for FY2025 Financial Results
26/01/2026
Tokyo, Japan and Cambridge, UK, 26 January 2026 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2025 on Friday, 13 February [...]
HighLife Receives CE Mark Approval for its TMVR Solution
26/01/2026
HighLife Receives CE Mark Approval for its TMVR Solution Paris, January 26, 2026 – HighLife SAS, a leading MedTech company focused on transcatheter solutions for structural heart disease, today announced that it has [...]
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
26/01/2026
Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- MannKind [...]
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
26/01/2026
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-point improvement in [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
26/01/2026
COPENHAGEN, Denmark, January 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]
Lake Erie College of Osteopathic Medicine Designs Medical Education Around Multiple Learning Pathways to Support Different Learning Styles
26/01/2026
Erie, PA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Medical education is often delivered through a single instructional format, but Lake Erie College of Osteopathic Medicine (LECOM) is taking a different approach by designing [...]
HighLife Receives CE Mark Approval for its TMVR Solution
26/01/2026
HighLife Receives CE Mark Approval for its TMVR Solution Paris, January 26, 2026 – HighLife SAS, a leading MedTech company focused on transcatheter solutions for structural heart disease, today announced that it has [...]
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
26/01/2026
ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
26/01/2026
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date set for May [...]

Pages